+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Infusion Devices market set to grow to $2.9bn by 2022” says new Visiongain report

16 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres

Infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices, the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat. For example, both the cancer and diabetes markets are on the rise.

The lead analyst of the report commented "With improved regulations, new infusion pump systems hitting the market are safer, more effective, and are becoming increasingly technologically advanced. This has come at a time when a shift between hospital and home care is happening across the world, though particularly in Europe.

The shift in demand from hospitals to home care settings has been particularly advantageous for insulin pumps, patient-controlled analgesia pumps, and ambulatory pumps due to the increased acceptance by patients and focus for the reduction of overall treatment costs associated with longer hospital stays."

Leading companies featured in the report include Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CME Medical UK Ltd., Fresenius SE & Co. KGaA, ICU Medical, Inc., Johnson & Johnson, Moog Inc., Smiths Group plc, Terumo Medical Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read